Krystal Biotech, Inc.

KRYS

$183.02

Name : Krystal Biotech, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $5,297,144,320.00

EPSttm : 4.92

Krystal Biotech, Inc.

$183.02

1.36%

$2.45

Float Short %

14.5

Margin Of Safety %

-7

Put/Call OI Ratio

2.7

EPS Next Q Diff

-0.04

EPS Last/This Y

1.8

EPS This/Next Y

3.39

Price

183.23

Target Price

205.82

Analyst Recom

1.17

Performance Q

22.91

Relative Volume

0.59

Beta

0.64

Ticker: KRYS

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-08	KRYS	145.22	2.71	0.01	10269
2025-09-09	KRYS	140.91	2.62	0.13	10369
2025-09-10	KRYS	137.31	2.58	0.53	10410
2025-09-11	KRYS	144.18	2.48	0.02	10655
2025-09-12	KRYS	143.85	2.56	0.48	10571
2025-09-15	KRYS	155.99	2.53	0.33	10525
2025-09-16	KRYS	154.26	2.48	0.02	10634
2025-09-17	KRYS	154.05	2.4546341463415	0.58620689655172	10623
2025-09-18	KRYS	160.57	2.45	0.04	10627
2025-09-19	KRYS	163.9	2.33	0.06	10789
2025-09-22	KRYS	165.54	2.68	0.04	9643
2025-09-23	KRYS	165.09	2.64	0.15	9673
2025-09-24	KRYS	162.03	2.74	0.47	9928
2025-09-25	KRYS	161.15	2.73	0.01	9920
2025-09-26	KRYS	168.03	2.73	0.96	9928
2025-09-29	KRYS	176.88	2.72	0.71	9934
2025-09-30	KRYS	176.47	2.74	0.21	9976
2025-10-01	KRYS	179.49	2.71	0.60	10024
2025-10-02	KRYS	181.73	2.70	3.29	10049
2025-10-03	KRYS	183.57	2.71	0.23	10090
2025-10-06	KRYS	180.55	2.70	0.01	10099
2025-10-07	KRYS	183.23	2.70	0.04	10110
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-08	KRYS	145.20	-13.0	165.6	4.92
2025-09-09	KRYS	141.09	-13.0	167.6	4.92
2025-09-10	KRYS	137.45	-13.0	168.3	4.92
2025-09-11	KRYS	144.36	-13.0	198.8	4.92
2025-09-12	KRYS	143.98	-13.0	177.7	4.92
2025-09-15	KRYS	155.85	-13.0	212.2	4.92
2025-09-16	KRYS	154.38	-13.0	175.5	4.92
2025-09-17	KRYS	154.01	-13.0	177.9	4.92
2025-09-18	KRYS	160.52	-13.0	194.9	4.92
2025-09-19	KRYS	163.61	-13.0	186.0	4.92
2025-09-22	KRYS	165.42	-13.0	182.6	4.92
2025-09-23	KRYS	164.96	-13.0	177.7	4.92
2025-09-24	KRYS	161.96	-13.0	171.7	4.92
2025-09-25	KRYS	161.15	-13.0	176.7	4.92
2025-09-26	KRYS	167.82	-13.0	194.8	4.92
2025-09-29	KRYS	176.88	-13.0	199.5	4.92
2025-09-30	KRYS	176.62	-13.0	178.5	4.92
2025-10-01	KRYS	179.77	-13.0	185.8	4.92
2025-10-02	KRYS	181.59	-13.0	183.0	4.92
2025-10-03	KRYS	183.54	-13.0	182.6	4.92
2025-10-06	KRYS	180.27	-13.0	175.8	4.92
2025-10-07	KRYS	183.23	-13.0	184.4	4.92
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-08	KRYS	-4.67	0.47	14.01
2025-09-09	KRYS	-4.67	0.47	14.01
2025-09-10	KRYS	-4.67	0.47	14.01
2025-09-11	KRYS	-4.67	0.47	13.87
2025-09-12	KRYS	-4.67	0.47	13.87
2025-09-15	KRYS	-2.39	0.49	13.87
2025-09-16	KRYS	-2.39	0.49	13.87
2025-09-17	KRYS	-2.39	0.49	13.87
2025-09-18	KRYS	-2.39	0.49	13.87
2025-09-19	KRYS	-2.39	0.49	13.87
2025-09-22	KRYS	-2.39	0.51	13.87
2025-09-23	KRYS	-2.39	0.51	13.87
2025-09-24	KRYS	-2.39	0.51	13.87
2025-09-25	KRYS	-2.39	0.51	14.50
2025-09-26	KRYS	-2.39	0.51	14.50
2025-09-29	KRYS	-2.39	0.51	14.50
2025-09-30	KRYS	-2.39	0.51	14.50
2025-10-01	KRYS	-2.39	0.51	14.50
2025-10-02	KRYS	-2.39	0.51	14.50
2025-10-03	KRYS	-2.39	0.51	14.50
2025-10-06	KRYS	-2.39	0.74	14.50
2025-10-07	KRYS	-2.39	0.74	14.50
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

1.29

Avg. EPS Est. Current Quarter

1.12

Avg. EPS Est. Next Quarter

1.25

Insider Transactions

-2.39

Institutional Transactions

0.74

Beta

0.64

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

105

Fair Value

170.94

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

16.5

Max Drawdown 5-Year %

-53.4

Target Price

205.82

P/E

37.23

Forward P/E

23.33

PEG

0.65

P/S

14.75

P/B

5.09

P/Free Cash Flow

28.57

EPS

4.92

Average EPS Est. Cur. Y

4.92

EPS Next Y. (Est.)

8.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

40.85

Relative Volume

0.59

Return on Equity vs Sector %

-11.1

Return on Equity vs Industry %

2.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.19

EBIT Estimation

184.4

Krystal Biotech, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 275

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today

news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance

stock history KRYS – Krystal Biotech, Inc. invest stock market

stock prices KRYS premarket after hours

ticker KRYS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KRYS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y